Drug development in the age of artificial intelligence
Artificial intelligence is fundamentally transforming drug development – making it faster, more efficient and data-driven. However, the more powerful the systems become, the greater the regulatory challenges. New guidelines from Swissmedic, the WHO and international organisations show that without clear governance, there is a risk to patient safety and market integrity. Companies are faced with the question of how to ensure both innovation and compliance at the same time.